## Weekly update on Variants of Concern (VOC)

Nov 5, 2021

Of all positive samples sequenced in epi week 42 (Oct 17 - Oct 23) in BC,  $\sim$  100% were confirmed VOCs (Figure 1). VOC prevalence was similar across Health Authorities.

Data from epi week 42 may reflect partial data; estimates are expected to change as more specimens are received and sequenced.




Figure 1. Prevalence of VOC, by epi week in BC and Health Authorities, Jan 3 - Oct 23, 2021

#### Epidemiological week (based on collection date)


Dash-dotted line indicates the time of transition to WGS of all positive samples on May 30, 2021 (epi week 22). Data from the PLOVER system at the BCCDC Public Health Lab.

Purple shaded box reflects partial data due to the results being available 7-11 days after the sample is received by the BCCDC Public Health Lab, and estimates for the latest epi week may change as more sequencing results come back.

The main circulating variant is Delta, accounting for about 100% of positive specimens sequenced.

Please note that the estimate of distribution of VOC lineage\* (Figure 2) in BC for latest epi week 42 (Oct 17 - Oct 23) may change as more sequencing results are analyzed and given the lag in receipt of positive samples from front line laboratories.

Figure 2. Estimated Sample prevalence<sup>^</sup> of VOCs by lineage by epi week of collection date, Jan 3 - Oct 23, 2021



A Sample prevalence is calculated as the rate of occurrence of a given VOC lineage per 100 positive lab samples. It was estimated from the proportion of presumptive VOC from screening and the proportion of confirmed VOC via sequencing (excluding outbreaks and targeted surveillance) until May 30th, 2021 when BC transitioned to WGS on all positive cases. From week 13 (March 28, 2021), VOC screening results with both E484K and N501Y mutations are assumed to be Gamma, given a very low prevalence of Beta in BC. As of week 22 (May 30, 2021), prevalence of VOC is estimated from sequencing results only.

Pink shaded box can reflect partial data due to a lag in receipt of positive samples from front line laboratories and turn around time of 7 to 11 days from sample collection to WGS analysis; estimates are expected to change as more specimens are received and sequenced.

# See appendix for the definitions of VOC lineages

Table 1. Sequencing-based VOC prevalence and approximate distribution by VOC lineage in BC and Health Authorities, latest available estimates\* on epi week 42 (Oct 17 - Oct 23).

| Region | Total<br>positive<br>tests | Sample  | prevalence** | Relative Proportion of VOC*** |         |         |            |
|--------|----------------------------|---------|--------------|-------------------------------|---------|---------|------------|
|        |                            | % Alpha | % Delta      | % Gamma                       | % Alpha | % Delta | %<br>Gamma |
| ВС     | 4484                       | 0       | 100          | 0                             | 0       | 100     | 0          |
| FHA    | 1972                       | 0       | 100          | 0                             | 0       | 100     | 0          |
| IHA    | 652                        | 0       | 100          | 0                             | 0       | 100     | 0          |
| NHA    | 840                        | 0       | 100          | 0                             | 0       | 100     | 0          |
| VCH    | 498                        | 0       | 100          | 0                             | 0       | 100     | 0          |
| VIHA   | 500                        | 0       | 100          | 0                             | 0       | 100     | 0          |

<sup>\*</sup>Note: Due to the lag in receipt of positive samples from front line laboratories the reported estimates for VoC by Health Authorities are expected to change as more specimens are received and sequenced. Due to rounding, estimates may add to more than 100.

<sup>\*\*</sup> Sample prevalence is calculated as the rate of occurrence of a given VOC lineage per 100 positive lab samples. It is estimated from the proportion of confirmed VOC via sequencing. Note, before epi week 22, sample prevalence was previously calculated using both screening and sequencing data. Due to rounding, individual VoC estimates may not match the overall VoC prevalence.


<sup>\*\*\*</sup>Relative Proportion from the total VOC identified through sequencing. The proportion for Beta not shown in this table due to small numbers. Note, before epi week 22, relative proportions were previously calculated using both screening and sequencing data. The proportion for Beta not shown in this table due to small numbers.

# See appendix for the definitions of VOC lineages

### Variants of Interests (VOI)

As illustrated in Figure 3 below, BCCDC Public Health Lab is continuously monitoring for both VOCs and VOIs. There are numerous VOIs, and they may not necessarily become VOCs. Once a VOI becomes a VOC, it will be added to our VOC reporting. Since September 2021 BC has adopted a new sampling strategy for sequencing to report on the provincial number of variants based on weekly point prevalence.

Figure 3. Overview of the screening and sequencing process applied to positive COVID-19 tests in BC, Oct 2021.



Please note the turnaround time sequencing which takes approximately 7-11 days, but it could also take longer if there are lab backlogs or if there are delays in receiving current positive samples from front line laboratories.

# Whole genome sequencing (WGS)

Whole genome sequencing (Illumina only) was performed on 87,692 specimens up to epi week 42 (Oct 17 - Oct 23) in BC, of which 67,693 came back as variants under closer observation. Table 2 below presents the number of variant samples sequenced; it does not represent the number of variant COVID cases. As illustrated in Figure 3 above, BC has transitioned to whole genome sequencing on all positive samples.

Table 2: Frequencies of SARS-CoV-2 monitored genetic lineages confirmed by WGS.

| Identified Lineage* (Pangolin version 3.1.15/PangoLEARN2021-10-15) | WHO Name | Category** | First Detected  | TOTAL | % Change since last report |
|--|----------|------------|-----------------|-------|----------------------------|
| B.1.1.7  | Alpha    | VOC        | UK              | 14673 | 0                          |
| Q.*  | Alpha    | VOC        | UK              | 355   | 0                          |
| B.1.351  | Beta     | VOC        | South Africa    | 159   | 0                          |
| B.1.351.*  | Beta     | VOC        | South Africa    | 2     | 0                          |
| B.1.617.2  | Delta    | VOC        | India           | 4155  | 5.0                        |
| AY.*   | Delta    | VOC        | India           | 33998 | 10.6                       |
| P.1  | Gamma    | VOC        | Brazil/Japan    | 54    | 0                          |
| P.1.*  | Gamma    | VOC        | Brazil          | 11863 | 0                          |
| A.23.1   |          | VOI        | TBC             | 35    | 0                          |
| AZ.1   |          | VOI        |                 | 6     | 0                          |
| AZ.2   |          | VOI        |                 | 0     |                            |
| AZ.2.1   |          | VOI        |                 | 0     |                            |
| AZ.3   |          | VOI        |                 | 0     |                            |
| AZ.4   |          | VOI        |                 | 0     |                            |
| AZ.5   |          | VOI        |                 | 4     | 0                          |
| AZ.6   |          | VOI        |                 | 0     |                            |
| B.1.1.318  |          | VOI        | Switzerland     | 20    | 0                          |
| B.1.427  | Epsilon  | VOI        | California, USA | 4     | 0                          |
| B.1.429  | Epsilon  | VOI        | California, USA | 838   | 0                          |
| B.1.525  | Eta      | VOI        | Nigeria         | 151   | 0                          |
| B.1.526  | lota     | VOI        | New York, USA   | 12    | 0                          |
| B.1.526.1  | lota     | VOI        | New York, USA   | 0     |                            |
| B.1.616  |          | VOI        | France          | 0     |                            |
| B.1.617.1  | Карра    | VOI        | India           | 403   | 0                          |

| B.1.617.3 |        | VOI | India         | 3   | 0    |
|-----------|--------|-----|---------------|-----|------|
| B.1.621   | Mu     | VOI | Colombia      | 37  | 0    |
| B.1.621.1 | Mu     | VOI | Colombia      | 9   | 0    |
| C.37      | Lambda | VOI | Chile         | 1   | 0    |
| P.3       | Theta  | VOI | Philippines   | 4   | 0    |
| A.2.5     |        | VUM |               | 3   | 0    |
| A.27      |        | VUM |               | 0   |      |
| A.28      |        | VUM |               | 0   |      |
| A.29      |        | VUM |               | 0   |      |
| A.30      |        | VUM |               | 0   |      |
| AT.1      |        | VUM |               | 0   |      |
| AV.1      |        | VUM |               | 0   |      |
| B.1       |        | VUM |               | 132 | 3.8  |
| B.1.1.1   |        | VUM |               | 20  | 0    |
| B.1.1.28  |        | VUM |               | 4   | 0    |
| B.1.1.519 |        | VUM |               | 284 | 0    |
| B.1.1.523 |        | VUM |               | 0   |      |
| B.1.160   |        | VUM |               | 183 | 0    |
| B.1.214.2 |        | VUM |               | 0   |      |
| B.1.324   |        | VUM |               | 0   |      |
| B.1.466.2 |        | VUM |               | 0   |      |
| B.1.526.2 | lota   | VUM | New York, USA | 0   |      |
| B.1.618   |        | VUM | India         | 85  | 45.9 |
| B.1.619   |        | VUM |               | 1   | 0    |
| B.1.620   |        | VUM |               | 0   |      |
| B.1.628   |        | VUM |               | 0   |      |
| B.1.629   |        | VUM |               | 0   |      |
| B.1.630   |        | VUM |               | 0   |      |
| B.1.631   |        | VUM |               | 0   |      |
| C.1.2     |        | VUM | South Africa  | 0   |      |
| C.16      |        | VUM |               | 0   |      |
| C.36.3    |        | VUM |               | 0   |      |
| C.36.3.1  |        | VUM |               | 0   |      |

| P.2   | Zeta | VUM | Brazil | 194   | 0   |
|-------|------|-----|--------|-------|-----|
| R.1   |      | VUM |        | 1     | 0   |
| R.2   |      | VUM |        | 0     |     |
| TOTAL |      |     |        | 67693 | 5.7 |

<sup>\*</sup> Lineage assignments are based on the use of Pangolin, an epidemiological lineage assignment tool (github.com/cov-lineages/pangolin); these may change with time as new SARS-CoV-2 genomic data becomes available.

#### # Appendix — VOC Lineages Table

| voc   | Associated Lineages |  |
|-------|---------------------|--|
| Alpha | B.1.1.7, Q.*        |  |
| Beta  | B.1.351, B.1.351.*  |  |
| Gamma | P.1, P.1.*          |  |
| Delta | B.1.617.2, AY.*     |  |

<sup>\*</sup>indicates an additional numerical value (e.g. Q.1).

<sup>\*</sup> Please note that updates of the Pangolin tool may also result in the refinement of lineage and sublineage designations. See appendix for the definitions of VOC lineages

<sup>\*\*</sup> Variant category includes: Variant of Concern (VoC), Variant of Interest (VoI) and Variants under Monitoring (VuM).